Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 21, 2023, titled "Zydus receives final and tentative Approval from the USFDA for Tofacitinib Tablets, 5 mg and 10 mg, respectively".
Press Release Mar 21 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding approvals from the USFDA for Tofacitinib Tablets. The company received final approval for the five milligram strength and tentative approval for the ten milligram strength of the drug. Tofacitinib is used to treat various forms of arthritis and ulcerative colitis, and will be manufactured in Ahmedabad, India. The press release highlights Zydus's eligibility for shared exclusivity for the five milligram strength due to its early application.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 15 2023
- Press Release Mar 09 2023
- Press Release Mar 07 2023
- Press Release Mar 03 2023
- Press Release Mar 02 2023
Later from Zydus Lifesciences
- Press Release Mar 24 2023
- Press Release Mar 25 2023
- Press Release Mar 28 2023
- Press Release Apr 06 2023
- Press Release Apr 10 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences